Bruker
BRKR
$59.02
+5.34%
Bruker Corporation is a leading manufacturer of scientific instruments and diagnostic solutions, serving the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates through segments including BSI BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST), with BSI CALID being the largest revenue contributor. Bruker is recognized as a market leader in high-performance analytical instrumentation, differentiating itself through advanced technology and a broad portfolio that spans mass spectrometry, microscopy, and diagnostic testing. The current investor narrative centers on the company's strong growth trajectory, driven by demand for its scientific tools and a recent surge in stock price, though questions about valuation sustainability and margin expansion remain key points of debate.…
BRKR
Bruker
$59.02
Investment Opinion: Should I buy BRKR Today?
Based on the analysis, BRKR is rated a Hold. The stock has strong momentum and a solid product portfolio, but the current valuation is stretched given the lack of profitability. The average analyst target of $58.75 implies only 2.9% upside, suggesting the stock is fairly valued. The forward PE of 23.72x is reasonable if earnings recover as expected, but the negative trailing EPS introduces uncertainty.
Sign up to view all
BRKR 12-Month Price Forecast
The AI assessment is neutral, reflecting the balance between Bruker's strong market position and its current financial challenges. The stock's valuation is not excessive on a forward basis, but the lack of current profitability and modest growth cap upside. The key factor to watch is whether the company can achieve the earnings recovery implied by the forward PE. If revenue growth accelerates and margins improve, the stance would upgrade to bullish; if growth stalls or losses widen, it would downgrade to bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bruker's 12-month outlook, with a consensus price target around $58.75 and implied upside of -0.5% versus the current price.
Average Target
$58.75
0 analysts
Implied Upside
-0.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$40 - $70
Analyst target range
The wide target range suggests significant divergence in analyst views: the low target of $40.00 implies a downside of -29.9%, possibly factoring in margin compression or competitive pressures, while the high target of $70.00 implies an upside of 22.6%, likely assuming accelerating growth and successful execution of its strategic initiatives. Recent institutional ratings have been predominantly positive, with no downgrades in the past few months, and the consensus remains constructive. However, the relatively narrow upside to the average target suggests that the stock may be fairly valued at current levels, and investors should monitor the company's ability to meet earnings expectations.
Bulls vs Bears: BRKR Investment Factors
Bruker presents a mixed picture: strong price momentum and a solid product portfolio are offset by weak profitability and high valuation multiples. The bull case rests on the company's ability to translate its market leadership into sustained earnings growth, while the bear case highlights the risk of overvaluation if growth stalls. Currently, the bearish evidence is slightly stronger due to the negative EPS and high cash flow multiple, but the forward PE suggests optimism. The key tension is whether the company can achieve the earnings recovery implied by the forward PE, which would validate the current valuation.
Bullish
- Strong 1-Year Price Performance: BRKR has delivered a 70.59% return over the past year, significantly outperforming the S&P 500's 18.56% gain. This demonstrates strong market confidence and momentum, reflecting successful execution of its growth strategy.
- Revenue Growth and Diversified Segments: The company reported Q1 2026 revenue of $823.4 million, a 2.75% YoY increase, with a diversified portfolio across life sciences and diagnostics. The BSI CALID segment, the largest, provides a stable revenue base, while other segments offer growth potential.
- Healthy Gross Margin: Gross margin stands at 45.9% (TTM), indicating strong pricing power and efficient cost management. This is a key competitive advantage in the scientific instruments industry, supporting profitability despite modest revenue growth.
- Positive Analyst Sentiment: With 12 analysts covering the stock, the average target price is $58.75, implying a modest upside of 2.9% from the current price of $57.08. No recent downgrades and a consensus constructive view suggest analysts see continued potential.
Bearish
- Negative Trailing EPS and Thin Margins: BRKR's trailing twelve-month EPS is -$0.0012, and the net margin is -0.25%, indicating the company is barely breaking even. Operating margin is only 6.87%, leaving little room for error or unexpected costs.
- High Valuation on Sales and Cash Flow: The PS ratio of 2.08x, while below historical averages, is still elevated for a company with negative earnings. The PCF ratio of 53.33x is particularly high, suggesting the market is paying a premium for cash flow that is currently constrained.
- Recent Price Volatility and Pullback: The stock has pulled back from its 52-week high of $65.30 to $57.08, a decline of 12.6%. The 1-month price change is -7.55%, and the stock has underperformed the S&P 500 by 13.02% over the past month, indicating waning momentum.
- Elevated Debt Levels: The debt-to-equity ratio of 0.83 indicates a moderate but notable debt burden. With interest expenses of $12.2 million in Q1 2026, the company's profitability is sensitive to interest rate changes and debt servicing costs.
BRKR Technical Analysis
Bruker's stock has exhibited a robust long-term uptrend, with a 1-year price change of +70.59%, significantly outperforming the S&P 500's +18.56% over the same period. The current price of $57.08 sits at 87.4% of its 52-week range (between $28.53 low and $65.30 high), indicating the stock is trading near its highs, reflecting strong momentum but also potential overextension. The 6-month price change of +42.31% further underscores the sustained bullish trend, though the stock has pulled back from its July peak of $65.30, suggesting some consolidation.
Beta
1.27
1.27x market volatility
Max Drawdown
-39.9%
Largest decline past year
52-Week Range
$29-$65
Price range past year
Annual Return
+77.6%
Cumulative gain past year
| Period | BRKR Return | S&P 500 |
|---|---|---|
| 1m | -8.2% | +1.0% |
| 3m | -1.6% | +1.1% |
| 6m | +60.9% | +13.8% |
| 1y | +77.6% | +19.5% |
| ytd | +22.7% | +12.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BRKR Fundamental Analysis
Bruker's revenue trajectory shows moderate growth, with the most recent quarter (Q1 2026) reporting revenue of $823.4 million, a 2.75% year-over-year increase. This growth is a slowdown compared to the prior year's Q1 (which saw revenue of $801.4 million), and the quarterly trend has been uneven, with Q4 2025 revenue of $977.2 million and Q3 2025 at $860.5 million. The company's revenue is driven primarily by its product sales, which accounted for $646.4 million in the latest quarter, with services and other contributing $177.0 million. The modest growth rate suggests a mature market, but the company's focus on high-end scientific instruments positions it well for long-term demand.
Quarterly Revenue
$823400000.0B
2026-03
Revenue YoY Growth
+2.8%
YoY Comparison
Gross Margin
47.3%
Latest Quarter
Free Cash Flow
$51300000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BRKR Overvalued?
Given that Bruker's trailing twelve-month net income is negative (EPS of -$0.0012), the price-to-sales (PS) ratio is the most appropriate valuation metric, as it provides a meaningful comparison despite the lack of profitability. The current PS ratio stands at 2.08x, which is a significant discount to the company's historical average PS of around 12x over the past few years, indicating that the market is currently valuing the stock more conservatively relative to sales. However, the forward PE ratio of 23.72x suggests that analysts expect earnings to recover strongly, implying the market is pricing in a return to profitability.
PE
-314.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~206x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Bruker's most immediate risk is its thin profitability. The trailing EPS is essentially zero, and the net margin is -0.25%, meaning the company is barely covering costs. The operating margin of 6.87% provides a slim buffer, and any increase in input costs or R&D expenses could push the company into a loss. The debt-to-equity ratio of 0.83 indicates a moderate debt load, and with interest expenses of $12.2 million in Q1 2026, rising interest rates could pressure earnings. Additionally, the company's free cash flow is only $51.3 million TTM, which is low relative to its market cap, limiting financial flexibility.
FAQ
The key risks are: 1) Financial: The company has negative trailing EPS and a thin net margin of -0.25%, making it vulnerable to cost increases. 2) Competitive: Bruker faces intense competition from larger players like Thermo Fisher and Danaher, which could pressure pricing and market share. 3) Macro: With a beta of 1.275, the stock is more volatile than the market, and a downturn could hit demand for scientific instruments. 4) Company-specific: The high debt-to-equity ratio of 0.83 and low free cash flow of $51.3 million limit financial flexibility.
The 12-month forecast is mixed. In the base case (50% probability), the stock trades around $58.75, the analyst average target, with limited upside. In the bull case (30% probability), it could reach $70, driven by strong earnings and growth. In the bear case (20% probability), it could fall to $40 if growth stalls or losses widen. The most likely scenario is the base case, assuming the company maintains its current trajectory.
BRKR is fairly valued based on forward earnings, with a forward PE of 23.72x, which is reasonable for a growth company. However, on a trailing basis, the negative EPS makes the PE meaningless. The PS ratio of 2.08x is below its historical average of ~12x, suggesting the stock is not overvalued on sales. The PCF ratio of 53.33x is high, indicating the market is paying a premium for cash flow. Overall, the valuation is not extreme, but it assumes a significant earnings recovery.
BRKR is a Hold for most investors. The stock has strong momentum, with a 70.59% gain over the past year, and the forward PE of 23.72x suggests earnings recovery. However, the negative trailing EPS and high PCF ratio of 53.33x indicate risk. The average analyst target of $58.75 offers only 2.9% upside, so the risk/reward is balanced. It could be a good buy if you believe in the company's long-term growth and are willing to wait for profitability, but it's not a compelling value at current levels.
BRKR is more suitable for long-term investment due to its growth potential and current lack of profitability. The stock has a beta of 1.275, indicating high volatility, which makes it risky for short-term trading. The company's focus on high-end scientific instruments provides a solid foundation for long-term demand, but the near-term financials are weak. A minimum holding period of 3-5 years is recommended to allow for earnings recovery and potential re-rating.